Literature DB >> 8997562

Molecular epidemiology of Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans in a cystic fibrosis center.

H Vu-Thien1, D Moissenet, M Valcin, C Dulot, G Tournier, A Garbarg-Chenon.   

Abstract

Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans have been isolated with increasing frequency from the sputum of patients with cystic fibrosis in a pediatric hospital. In 1994-95, 27 of 120 patients were persistently colonized, 17 with Burkholderia cepacia, eight with Alcaligenes xylosoxidans, and five with Stenotrophomonas maltophilia. Genotyping of 220 clinical isolates revealed that most of the Burkholderia cepacia strains were clonally related, suggesting either cross-infection or a common source of exposure. In contrast, neither cross-infection nor a common source of exposure appear to have occurred in the cases of Alcaligenes xylosoxidans or Stenotrophomonas maltophilia.

Entities:  

Mesh:

Year:  1996        PMID: 8997562     DOI: 10.1007/bf01691221

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  13 in total

1.  Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis.

Authors:  J R Govan; P H Brown; J Maddison; C J Doherty; J W Nelson; M Dodd; A P Greening; A K Webb
Journal:  Lancet       Date:  1993-07-03       Impact factor: 79.321

Review 2.  Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing.

Authors:  F C Tenover; R D Arbeit; R V Goering; P A Mickelsen; B E Murray; D H Persing; B Swaminathan
Journal:  J Clin Microbiol       Date:  1995-09       Impact factor: 5.948

3.  Investigation of hospital-acquired infections due to Alcaligenes denitrificans subsp. xylosoxydans by DNA restriction fragment length polymorphism.

Authors:  M Cheron; E Abachin; E Guerot; M el-Bez; M Simonet
Journal:  J Clin Microbiol       Date:  1994-04       Impact factor: 5.948

4.  Occurrence and antimicrobial susceptibility of gram-negative nonfermentative bacilli in cystic fibrosis patients.

Authors:  J D Klinger; M J Thomassen
Journal:  Diagn Microbiol Infect Dis       Date:  1985-03       Impact factor: 2.803

5.  Source of Pseudomonas cepacia: ribotyping of isolates from patients and from the environment.

Authors:  M C Fisher; J J LiPuma; S E Dasen; G C Caputo; J E Mortensen; K L McGowan; T L Stull
Journal:  J Pediatr       Date:  1993-11       Impact factor: 4.406

6.  Arbitrarily primed polymerase chain reaction as a rapid method to differentiate crossed from independent Pseudomonas cepacia infections in cystic fibrosis patients.

Authors:  E H Bingen; M Weber; J Derelle; N Brahimi; N Y Lambert-Zechovsky; M Vidailhet; J Navarro; J Elion
Journal:  J Clin Microbiol       Date:  1993-10       Impact factor: 5.948

7.  Recovery of Pseudomonas cepacia and other Pseudomonas species from the environment.

Authors:  J E Mortensen; M C Fisher; J J LiPuma
Journal:  Infect Control Hosp Epidemiol       Date:  1995-01       Impact factor: 3.254

8.  Epidemiological investigation of infections due to Alcaligenes species in children and patients with cystic fibrosis: use of repetitive-element-sequence polymerase chain reaction.

Authors:  W M Dunne; S Maisch
Journal:  Clin Infect Dis       Date:  1995-04       Impact factor: 9.079

9.  Person-to-person transmission of Pseudomonas cepacia between patients with cystic fibrosis.

Authors:  J J LiPuma; S E Dasen; D W Nielson; R C Stern; T L Stull
Journal:  Lancet       Date:  1990-11-03       Impact factor: 79.321

10.  Transmissibility of Pseudomonas cepacia infection in clinic patients and lung-transplant recipients with cystic fibrosis.

Authors:  S Steinbach; L Sun; R Z Jiang; P Flume; P Gilligan; T M Egan; R Goldstein
Journal:  N Engl J Med       Date:  1994-10-13       Impact factor: 91.245

View more
  24 in total

1.  A new highly discriminatory multiplex capillary-based MLVA assay as a tool for the epidemiological survey of Pseudomonas aeruginosa in cystic fibrosis patients.

Authors:  D Sobral; P Mariani-Kurkdjian; E Bingen; H Vu-Thien; K Hormigos; B Lebeau; F Loisy-Hamon; A Munck; G Vergnaud; C Pourcel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-02-11       Impact factor: 3.267

2.  Persistent airway colonization with Alcaligenes xylosoxidans in two brothers with cystic fibrosis.

Authors:  H Peltroche-Llacshuanga; H Peltroche-Llacsahuanga; H Kentrup; G Haase
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-02       Impact factor: 3.267

3.  Achromobacter xylosoxidans Cellular Pathology Is Correlated with Activation of a Type III Secretion System.

Authors:  Adam M Pickrum; Orlando DeLeon; Aaron Dirck; Maxx H Tessmer; Molly O Riegert; Julie A Biller; Nathan A Ledeboer; John R Kirby; Dara W Frank
Journal:  Infect Immun       Date:  2020-06-22       Impact factor: 3.441

4.  Prevalence and Outcomes of Achromobacter Species Infections in Adults with Cystic Fibrosis: a North American Cohort Study.

Authors:  B D Edwards; J Greysson-Wong; R Somayaji; B Waddell; F J Whelan; D G Storey; H R Rabin; M G Surette; M D Parkins
Journal:  J Clin Microbiol       Date:  2017-04-26       Impact factor: 5.948

5.  Identification and antimicrobial susceptibility of Alcaligenes xylosoxidans isolated from patients with cystic fibrosis.

Authors:  L Saiman; Y Chen; S Tabibi; P San Gabriel; J Zhou; Z Liu; L Lai; S Whittier
Journal:  J Clin Microbiol       Date:  2001-11       Impact factor: 5.948

6.  Cathelicidin peptides inhibit multiply antibiotic-resistant pathogens from patients with cystic fibrosis.

Authors:  L Saiman; S Tabibi; T D Starner; P San Gabriel; P L Winokur; H P Jia; P B McCray; B F Tack
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

7.  Shared genotypes of Achromobacter xylosoxidans strains isolated from patients at a cystic fibrosis rehabilitation center.

Authors:  Sabine Van Daele; Rita Verhelst; Geert Claeys; Gerda Verschraegen; Hilde Franckx; Leen Van Simaey; Catharine de Ganck; Frans De Baets; Mario Vaneechoutte
Journal:  J Clin Microbiol       Date:  2005-06       Impact factor: 5.948

8.  Comparison of randomly amplified polymorphic DNA analysis and pulsed-field gel electrophoresis for typing of Moraxella catarrhalis strains.

Authors:  H Vu-Thien; C Dulot; D Moissenet; B Fauroux; A Garbarg-Chenon
Journal:  J Clin Microbiol       Date:  1999-02       Impact factor: 5.948

Review 9.  Infection control in cystic fibrosis.

Authors:  Lisa Saiman; Jane Siegel
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

10.  Sphingobacterium respiratory tract infection in patients with cystic fibrosis.

Authors:  Antonietta Lambiase; Fabio Rossano; Mariassunta Del Pezzo; Valeria Raia; Angela Sepe; Fabiola de Gregorio; Maria Rosaria Catania
Journal:  BMC Res Notes       Date:  2009-12-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.